CD8A and neoplasm: Tumor cells pre-treated with 5 μM elraglusib for 24 h and then co-cultured with donor-derived CD8+ T cells had an average of 65% dead cells, while co-cultures treated with 10 μM of elraglusib for 24 h and then co-cultured with donor-derived CD8+ T cells had an average of 70% dead cells (Figure 1F).